Department of Pathology, University Health Network and University of Toronto, Toronto, ON, Canada.
Mod Pathol. 2011 Jan;24(1):16-25. doi: 10.1038/modpathol.2010.156. Epub 2010 Sep 3.
The 2009 International Society of Urological Pathology consensus conference in Boston made recommendations regarding the standardization of pathology reporting of radical prostatectomy specimens. Issues relating to the substaging of pT2 prostate cancers according to the TNM 2002/2010 system, reporting of tumor size/volume and zonal location of prostate cancers were coordinated by working group 2. A survey circulated before the consensus conference demonstrated that 74% of the 157 participants considered pT2 substaging of prostate cancer to be of clinical and/or academic relevance. The survey also revealed a considerable variation in the frequency of reporting of pT2b substage prostate cancer, which was likely a consequence of the variable methodologies used to distinguish pT2a from pT2b tumors. Overview of the literature indicates that current pT2 substaging criteria lack clinical relevance and the majority (65.5%) of conference attendees wished to discontinue pT2 substaging. Therefore, the consensus was that reporting of pT2 substages should, at present, be optional. Several studies have shown that prostate cancer volume is significantly correlated with other clinicopathological features, including Gleason score and extraprostatic extension of tumor; however, most studies fail to demonstrate this to have prognostic significance on multivariate analysis. Consensus was reached with regard to the reporting of some quantitative measure of the volume of tumor in a prostatectomy specimen, without prescribing a specific methodology. Incorporation of the zonal and/or anterior location of the dominant/index tumor in the pathology report was accepted by most participants, but a formal definition of the identifying features of the dominant/index tumor remained undecided.
2009 年在波士顿举行的国际泌尿病理学会共识会议就前列腺根治性切除术标本的病理报告标准化提出了建议。与根据 TNM 2002/2010 系统对 pT2 前列腺癌进行亚分期、报告肿瘤大小/体积和前列腺癌的区域位置相关的问题,由工作组 2 进行协调。在共识会议之前进行的一项调查显示,157 名参与者中有 74%认为前列腺癌 pT2 亚分期具有临床和/或学术意义。该调查还显示,报告 pT2b 亚分期前列腺癌的频率存在相当大的差异,这可能是由于用于区分 pT2a 与 pT2b 肿瘤的方法不同所致。文献综述表明,目前的 pT2 亚分期标准缺乏临床相关性,大多数(65.5%)与会者希望停止 pT2 亚分期。因此,共识是目前报告 pT2 亚分期应该是可选的。有几项研究表明,前列腺癌体积与其他临床病理特征(包括 Gleason 评分和肿瘤的前列腺外扩展)显著相关;然而,大多数研究未能证明这在多变量分析中有预后意义。关于在前列腺切除术标本中报告肿瘤体积的某些定量测量值的报告达成了共识,而没有规定具体的方法。大多数参与者接受了在病理报告中纳入肿瘤优势/指数的区域和/或前位的方法,但优势/指数肿瘤的识别特征仍未确定。